Immunocore Holdings To Present 5-Yr OS From KIMMTRAK Phase 3 Trial In Previously Untreated HLA-A*02:01 Positive Patients With Unresected Or mUM, At 2026 AACR Annual Meeting

Immunocore Holdings announced it will present five-year overall survival data from the KIMMTRAK Phase 3 trial at the 2026 AACR Annual Meeting, starting April 17, 2026. This data pertains to previously untreated HLA-A*02:01 positive patients with unresected or metastatic uveal melanoma. The presentation will include the longest overall survival follow-up in a randomized trial for this patient group, along with additional data on subsequent treatments and prognostic factors.